Filing Analysis
Envoy Medical, Inc. (COCH) has received a second Nasdaq staff notification on May 19, 2026, granting an additional 180-day compliance period (until November 16, 2026) to meet the $1.00 minimum bid price requirement after failing to regain compliance within the initial 180-day period that expired on May 18, 2026. The Company has formally notified Nasdaq of its intention to cure the deficiency via a reverse stock split if necessary, signaling the stock price remains below $1.00.
🚩 Red Flags
- Stock price has been below $1.00 for an extended period — failing to recover across an entire initial 180-day compliance window.
- Company explicitly intends to pursue a reverse stock split to meet bid price requirements, a classic distress signal for micro-cap stocks.
- Warrant exercise price of $11.50 is dramatically above current market price, rendering warrants deeply out-of-the-money and effectively worthless.
- Failure to regain compliance within the first 180-day period suggests limited organic buying pressure or investor demand.
- Second compliance deadline of November 16, 2026, creates a hard deadline; failure could result in delisting proceedings.
- Reverse stock split, if executed, may reduce per-share price sensitivity and could trigger further selling pressure post-split.
📋 Key Facts
- Original Nasdaq deficiency notice received: November 19, 2025, for failure to maintain $1.00 minimum bid price (Nasdaq Listing Rule 5550(a)(2)) for 30 consecutive business days.
- Initial 180-day compliance period expired May 18, 2026, without the Company regaining compliance.
- Second staff notification received May 19, 2026, granting a second 180-day compliance period ending November 16, 2026.
- Company remains listed on Nasdaq Capital Market during the Second Compliance Period.
- Company filed written notice to Nasdaq of its intention to cure the deficiency by effecting a reverse stock split, if necessary.
- Nasdaq confirmed the Company meets all other continued listing requirements except the bid price requirement.
- Warrants (COCHW) also listed on Nasdaq, exercisable at $11.50 per share — well above current trading levels.
- Filing signed by CEO Brent Lucas on May 22, 2026.
- Company is classified as an emerging growth company.
Envoy Medical stockholders approved significant amendments to the company's equity incentive plans, authorizing an additional 7.2 million shares for issuance. The annual meeting also ratified the company's auditor and approved a prior warrant issuance to comply with Nasdaq listing rules.
🚩 Red Flags
- Significant potential shareholder dilution resulting from the authorization of 7,200,000 new shares for equity plans.
- The need for retroactive stockholder approval for a February 2026 warrant issuance suggests the previous transaction may have exceeded Nasdaq's 20% dilution threshold.
📋 Key Facts
- Authorized an additional 6,000,000 shares for the 2023 Equity Incentive Plan.
- Authorized an additional 1,200,000 shares for the 2023 Employee Stock Purchase Plan.
- Stockholders approved the issuance of warrants and underlying Class A Common Stock from a February 12, 2026 transaction to comply with Nasdaq Listing Rule 5635(d).
- Brent T. Lucas and Susan J. Kantor were elected as Class III directors with terms expiring in 2029.
- EisnerAmper, LLP was ratified as the independent auditor for the fiscal year ending December 31, 2026.
Envoy Medical, Inc. reported its financial results for the fiscal quarter ended March 31, 2026. The results were furnished via a press release attached to the filing.
📋 Key Facts
- The filing reports financial results for the first quarter ended March 31, 2026.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- The report includes Exhibit 99.1, which is the press release dated March 11, 2026 (noting a possible typo in the exhibit date vs filing date).
- The filing was signed by CEO Brent Lucas on May 11, 2026.
Envoy Medical appointed Charles S. McKhann to its Board of Directors and Compensation Committee, increasing the board size from six to seven. Mr. McKhann is a veteran medical device executive with a history of leading companies through successful acquisitions by major players like Boston Scientific.
📋 Key Facts
- Charles S. McKhann appointed as a Class I director on April 15, 2026, with a term expiring in 2027.
- Board size increased from six to seven members to accommodate the appointment.
- Mr. McKhann was granted 100,000 stock options at an exercise price of $0.72 per share, vesting over 36 months.
- Mr. McKhann's background includes serving as CEO of Silk Road Medical and Apollo Endosurgery, both of which were acquired by Boston Scientific Corporation.
Envoy Medical, Inc. dismissed Grant Thornton LLP and appointed EisnerAmper LLP as its new independent auditor effective March 25, 2026. The company's previous audit reports for 2024 and 2025 included going concern warnings and identified material weaknesses in internal controls.
🚩 Red Flags
- Persistent 'going concern' language in audit reports for the last two consecutive fiscal years.
- Ongoing material weaknesses in internal control over financial reporting (2024 and 2025).
- The filing was signed by an Interim Chief Financial Officer (Robert Potashnick), which may indicate management instability.
📋 Key Facts
- Grant Thornton LLP was dismissed as the independent registered public accounting firm on March 25, 2026.
- EisnerAmper LLP was appointed for the fiscal year ending December 31, 2026, following a competitive process.
- Audit reports for fiscal years ended December 31, 2024, and December 31, 2025, contained explanatory paragraphs expressing substantial doubt about the Company’s ability to continue as a going concern.
- Material weaknesses in internal control over financial reporting were disclosed in the Company’s Annual Reports on Form 10-K for 2024 and 2025.
- No disagreements were reported between the Company and Grant Thornton on accounting principles, practices, or disclosures.
Envoy Medical, Inc. announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025, via a press release on March 23, 2026.
🚩 Red Flags
- Company continues to operate with an Interim CFO (Robert Potashnick).
📋 Key Facts
- Announcement of Q4 and FY 2025 financial results.
- Press release dated March 23, 2026, furnished under Item 2.02.
- Filing signed by Interim CFO Robert Potashnick on March 27, 2026.
- The company is an emerging growth company.
Envoy Medical has regained compliance with Nasdaq's minimum market value of listed securities requirement (Rule 5550(b)(2)). While the company is no longer at immediate risk of delisting, it will be subject to a one-year discretionary panel monitor by Nasdaq.
🚩 Red Flags
- The company is subject to a one-year discretionary panel monitor, which acts as a 'probationary' period where any subsequent non-compliance could lead to accelerated delisting.
- History of listing standard deficiencies requiring a Hearing Panel intervention.
📋 Key Facts
- Received Nasdaq confirmation of compliance on February 23, 2026.
- The compliance relates to Nasdaq Listing Rule 5550(b)(2) regarding market value.
- The company was previously under review by a Nasdaq Hearing Panel as of October 23, 2025.
- A discretionary panel monitor will be in effect for one year starting February 12, 2026, pursuant to Rule 5815(d)(4)(B).